No Data
No Data
Barclays Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $90
Barclays analyst Leon Wang maintains $Insmed(INSM.US)$ with a buy rating, and maintains the target price at $90.According to TipRanks data, the analyst has a success rate of 75.0% and a total average
H.C. Wainwright Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $70
H.C. Wainwright analyst Andrew Fein maintains $Insmed(INSM.US)$ with a buy rating, and maintains the target price at $70.According to TipRanks data, the analyst has a success rate of 47.4% and a total
Optimistic Buy Rating for Insmed's Brensocatib Based on Forthcoming ASPEN Data and Competitive Analysis
Insmed Is Maintained at Buy by Truist Securities
Insmed Is Maintained at Buy by Truist Securities
Truist Financial Maintains Insmed(INSM.US) With Buy Rating, Announces Target Price $88
Truist Financial analyst Nicole Germino maintains $Insmed(INSM.US)$ with a buy rating, and sets the target price at $88.According to TipRanks data, the analyst has a success rate of 53.6% and a total
Truist Adjusts Insmed PT to $88 From $68, Updates Model Post Commercial Day; Maintains Buy Rating
Insmed (INSM) has an average rating of buy and price targets ranging from $60 to $90, according to analysts polled by Capital IQ. Price: 65.88, Change: -1.12, Percent Change: -1.67
No Data